NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis $3.55 -0.03 (-0.84%) (As of 10/4/2024 08:51 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Skye Bioscience Stock (NASDAQ:SKYE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Skye Bioscience alerts:Sign Up Key Stats Today's Range$3.42▼$3.6750-Day Range$3.14▼$6.9952-Week Range$1.44▼$19.41Volume325,500 shsAverage Volume170,877 shsMarket Capitalization$99.64 millionP/E RatioN/ADividend YieldN/APrice Target$18.67Consensus RatingBuy Company OverviewSkye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Read More… Next opportunity for crypto millions (Ad)"Uptober" is here, and it's not just a clever name. Historically, October ignites crypto's most explosive gains. This year could be off the charts. Don't let this opportunity pass you by. In crypto, timing is everything. Go here to discover the #1 crypto set to dominate Uptober. Skye Bioscience Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks69th Percentile Overall ScoreSKYE MarketRank™: Skye Bioscience scored higher than 69% of companies evaluated by MarketBeat, and ranked 338th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingSkye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSkye Bioscience has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Skye Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Skye Bioscience are expected to decrease in the coming year, from ($1.06) to ($1.21) per share.Read more about Skye Bioscience's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.48% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Skye Bioscience has recently decreased by 1.74%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.48% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Skye Bioscience has recently decreased by 1.74%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News Sentiment0.89 News SentimentSkye Bioscience has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Skye Bioscience this week, compared to 2 articles on an average week.Search Interest4 people have searched for SKYE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows13 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 1,200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,750,352.00 in company stock.Percentage Held by InsidersOnly 0.73% of the stock of Skye Bioscience is held by insiders.Percentage Held by InstitutionsOnly 21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address SKYE Stock News Headlines3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't IgnoreCheck out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.October 4 at 10:47 AM | marketbeat.comInsider Selling: Skye Bioscience, Inc. (NASDAQ:SKYE) Director Sells 13,837 Shares of StockSeptember 13, 2024 | insidertrades.comThe panic button has already been pressedIf you missed it, my emergency election broadcast is now available on replay.October 6, 2024 | Porter & Company (Ad)Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) Price Target at $18.67October 5 at 9:59 AM | americanbankingnews.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by AnalystsOctober 5 at 9:59 AM | americanbankingnews.comIs Skye Bioscience, Inc. (SKYE) the Best Russell 2000 Stock to Buy According to Analysts?October 3 at 11:31 AM | msn.comScotiabank Initiates Coverage of Skye Bioscience (SKYE) with Sector Outperform RecommendationOctober 2, 2024 | msn.comOppenheimer Keeps Their Buy Rating on Prothena (PRTA)September 30, 2024 | markets.businessinsider.comSee More Headlines SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed this year? Skye Bioscience's stock was trading at $2.72 at the beginning of 2024. Since then, SKYE shares have increased by 30.5% and is now trading at $3.55. View the best growth stocks for 2024 here. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) issued its quarterly earnings results on Friday, August, 9th. The company reported ($0.20) EPS for the quarter, meeting analysts' consensus estimates of ($0.20). How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/09/2024Today10/06/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SKYE Previous SymbolNASDAQ:SKYE CUSIPN/A CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$18.67 High Stock Price Target$25.00 Low Stock Price Target$14.00 Potential Upside/Downside+425.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.83% Return on Assets-80.69% Debt Debt-to-Equity RatioN/A Current Ratio6.07 Quick Ratio6.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-20.88Miscellaneous Outstanding Shares28,068,000Free Float27,863,000Market Cap$99.64 million OptionableOptionable Beta1.78 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:SKYE) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.